Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776

Clinical Cancer Research

Volumn 19, Issue 16, 2013, Pages 4412-4421

  Engelke, Carl G ^a   Parsels, Leslie A ^a   Qian, Yushen ^a   Zhang, Qiang ^a   Karnak, David ^a   Robertson, Jordan R ^a   Tanska, Daria M ^a   Wei, Dongping ^a   Davis, Mary A ^a   Parsels, Joshua D ^a   Zhao, Lili ^b   Greenson, Joel K ^a   Lawrence, Theodore S ^a   Maybaum, Jonathan ^a   Morgan, Meredith A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; MK 8776; PROTEIN SERINE THREONINE KINASE INHIBITOR; RAD51 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHOSPHORYLATION; CANCER CELL; CHEMORADIOTHERAPY; CHEMOSENSITIZATION; CONTROLLED STUDY; DNA DAMAGE; DRUG EFFICACY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EX VIVO STUDY; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; RADIOSENSITIZATION; RECOMBINATION REPAIR; SMALL INTESTINE; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; WEIGHT REDUCTION;

ANIMALS; CELL LINE, TUMOR; CHEMORADIOTHERAPY; DEOXYCYTIDINE; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; MICE; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PYRAZOLES; PYRIMIDINES; RADIATION-SENSITIZING AGENTS; RECOMBINATIONAL DNA REPAIR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84883018226     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3748     Document Type: Article

References (35)

1. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-25.
2. Loehrer PJ Sr, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an eastern cooperative oncology group trial. J Clin Oncol 2011;29:4105-12.
3. Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 2009;27:1806-13.
4. Ben-Josef E, Lawrence TS. Radiotherapy: the importance of local control in pancreatic cancer. Nat Rev Clin Oncol 2012;9:9-10.
5. Ben-Josef E, Schipper M, Francis IR, Hadley S, Ten-Haken R, Lawrence T, et al. A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2012;84:1166-71.
6. Crane CH, Varadhachary GR, Yordy JS, Staerkel GA, Javle MM, Safran H, et al. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immu-nostaining with pattern of disease progression. J Clin Oncol 2011;29: 3037-43.
7. Sorensen CS, Hansen LT, Dziegielewski J, Syljuasen RG, Lundin C, Bartek J, et al. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol 2005;7: 195-201.
8. Morgan MA, Parsels LA, Zhao L, Parsels JD, Davis MA, Hassan MC, et al. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res 2010;70: 4972-81.
9. Ma CX, Janetka JW, Piwnica-Worms H. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol Med 2011;17: 88-96.
10. Mitchell JB, Choudhuri R, Fabre K, Sowers AL, Citrin D, Zabludoff SD, et al. In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762. Clin Cancer Res 2010; 16:2076-84.
11. Vance S, Liu E, Zhao L, Parsels JD, Parsels LA, Brown JL, et al. Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1. Cell Cycle 2011;10: 4321-9.
12. Guzi TJ, Paruch K, Dwyer MP, Labroli M, Shanahan F, Davis N, et al. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther 2011;10:591-602.
13. Carrassa L, Damia G. Unleashing Chk1 in cancer therapy. Cell Cycle 2011;10:2121-8.
14. Parsels LA, Qian Y, Tanska DM, Gross M, Zhao L, Hassan MC, et al. Assessment of chk1 phosphorylation as a pharmacodynamic bio-marker of chk1 inhibition. Clin Cancer Res 2011;17:3706-15.
15. McNeely S, Conti C, Sheikh T, Patel H, Zabludoff S, Pommier Y, et al. Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase. Cell Cycle 2010;9:995-1004.
16. Montano R, Chung I, Garner KM, Parry D, Eastman A. Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites. Mol Cancer Ther 2012;11:427-38.
17. Xia F, Taghian DG, DeFrank JS, Zeng ZC, Willers H, Iliakis G, et al. Deficiency of human BRCA2 leads to impaired homologous recombination but maintains normal nonhomologous end joining. Proc Natl Acad Sci U S A 2001;98:8644-9.
18. Fertil B, Dertinger H, Courdi A, Malaise EP. Mean inactivation dose: a useful concept for intercomparison of human cell survival curves. Radiat Res 1984;99:73-84.
19. Parsels LA, Morgan MA, Tanska DM, Parsels JD, Palmer BD, Booth RJ, et al. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells. Mol Cancer Ther 2009;8:45-54.
20. Morgan MA, Parsels LA, Kollar LE, Normolle DP, Maybaum J, Lawrence TS. The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer. Clin Cancer Res 2008;14:5142-9.
21. van Geer MA, Kuhlmann KF, Bakker CT, ten Kate FJ, Oude Elferink RP, Bosma PJ. Ex-vivo evaluation of gene therapy vectors in human pancreatic (cancer) tissue slices. World J Gastroenterol 2009;15: 1359-66.
22. Krejci L, Altmannova V, Spirek M, Zhao X. Homologous recombination and its regulation. Nucleic Acids Res 2012;40:5795-818.
23. Zhao L, Morgan MA, Parsels LA, Maybaum J, Lawrence TS, Normolle D. Bayesian hierarchical changepoint methods in modeling the tumor growth profiles in xenograft experiments. Clin Cancer Res 2011;17: 1057-64.
24. Leung-Pineda V, Ryan CE, Piwnica-Worms H. Phosphorylation of Chk1 by ATR is antagonized bya Chk1-regulated protein phosphatase 2A circuit. Mol Cell Biol 2006;26:7529-38.
25. Sorensen CS, Syljuasen RG. Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication. Nucleic Acids Res 2012;40:477-86.
26. Morgan MA, El Shaikh M, Abu-Isa E, Davis MA, Lawrence TS. Radiosensitization by gemcitabine fixed-dose-rate infusion versus bolus injection in a pancreatic cancer model. Transl Oncol 2008; 1:44-9.
27. Zhang YW, Otterness DM, Chiang GG, Xie W, Liu YC, Mercurio F, et al. Genotoxic stress targets human Chk1 for degradation by the ubiquitin-proteasome pathway. Mol Cell 2005;19:607-18.
28. Zabludoff SD, Deng C, Grondine MR, Sheehy AM, Ashwell S, Caleb BL, et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther 2008;7:2955-66.
29. Jobson AG, Lountos GT, Lorenzi PL, Llamas J, Connelly J, Cerna D, et al. Cellular inhibition of checkpoint kinase 2 (Chk2) and poten-tiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidino-hydrazone)-ethyl]-phenyl}- amide]. J Pharmacol Exp Ther 2009;331: 816-26.
30. Gilad O, Nabet BY, Ragland RL, Schoppy DW, Smith KD, Durham AC, et al. Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumori-genesis in a dosage-dependent manner. Cancer Res 2010;70: 9693-702.
31. Syljuasen RG, Sorensen CS, Hansen LT, Fugger K, Lundin C, Johansson F, et al. Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol Cell Biol 2005;25:3553-62.
32. Thompson R, Montano R, Eastman A. The mre11 nuclease is critical for the sensitivity of cells to chk1 inhibition. PLoS ONE 2012;7: e44021.
33. Forment JV, Blasius M, Guerini I, Jackson SP. Structure-specific DNA endonuclease Mus81/Eme1 generates DNA damage caused by Chk1 inactivation. PLoS ONE 2011;6:e23517.
34. Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997;57:1731-4.
35. Clark DP. Ex vivo biomarkers: functional tools to guide targeted drug development and therapy. Expert Rev Mol Diagn 2009;9: 787-94.